Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs 744

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 744 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Pipeline programs

Page 2 of 16

  1. Duloxetine hydrochloride

    Eli Lilly and Company

    Diabetic Neuropathies

    phase 3 small molecule completed

    1 trial

  2. Eloralintide

    Eli Lilly and Company

    Obesity

    phase 3 small molecule active

    1 trial

  3. Empagliflozin 10 MG

    Hospital Authority, Hong Kong

    Diabetic Nephropathies

    phase 3 small molecule terminated

    1 trial

  4. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial

  5. Faricimab

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  6. Fasiglifam (TAK-875)

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

  7. Faster-acting insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  8. Finerenone (BAY94-8862)

    Bayer HealthCare AG

    Diabetic Kidney Disease

    phase 3 small molecule completed

    1 trial

  9. Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  10. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  11. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial

  12. HS-20094 Injection

    Jian Li

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  13. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  14. I4V-MC-JAJJ

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  15. I6T-MC-AMCD

    Eli Lilly Co.

    Obesity or Overweight, Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  16. I6T-MC-AMCE

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  17. I8F-MC-GPGN

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  18. I8F-MC-GPHP

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  19. I8F-MC-GPIX

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  20. Inhaled Human Insulin

    Nektar Therapeutics UK Limited

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  21. Insulin Degludec and Insulin Aspart

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetes

    phase 3 small molecule completed

    1 trial

  22. Insulin degludec/insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  23. Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  24. Insulin icodec

    Novo Nordisk A/S

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial

  25. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  26. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  27. Intravitreal aflibercept injection [IAI]

    Regeneron UK Limited

    Nonproliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  28. J1I-MC-GZBO

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  29. J1I-MC-GZBP

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  30. J1I-MC-GZQD

    Eli Lilly Co.

    Overweight, Chronic Low Back Pain (CLBP), Obesity

    phase 3 small molecule active

    1 trial

  31. J2A-MC-GZGW

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  32. J2A-MC-GZPO

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  33. J3R-MC-YDAF

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  34. J3R-MC-YDAG

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  35. J3R-MC-YDAL

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  36. J3R-MC-YDAO

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 small molecule active

    1 trial

  37. K9531-3103

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  38. K9531-3104

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  39. K9531-3107

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  40. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    3 trials

  41. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 small molecule active

    1 trial

  42. Khalas dates

    United Therapeutics Europe Ltd

    Diabetes Mellitus

    phase 3 other completed

    1 trial

  43. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  44. LY2189265

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  45. Lapaquistat acetate and lipid-lowering therapy

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  46. Lifestyle modification

    Takeda

    Type 2 Diabetes

    phase 3 other completed

    1 trial

  47. Linagliptin

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  48. METFORMIN

    Pari Pharma GmbH

    Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

744 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.